GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Other Operating Expense

MBCOF (Marvel Biosciences) Other Operating Expense : $-0.08 Mil (TTM As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Other Operating Expense?

Marvel Biosciences's Other Operating Expense for the three months ended in Jan. 2025 was $-0.09 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2025 was $-0.08 Mil.

Marvel Biosciences's quarterly Other Operating Expense increased from Jul. 2024 ($0.00 Mil) to Oct. 2024 ($0.01 Mil) but then declined from Oct. 2024 ($0.01 Mil) to Jan. 2025 ($-0.09 Mil).

Marvel Biosciences's annual Other Operating Expense declined from Jul. 2022 ($0.04 Mil) to Jul. 2023 ($-0.04 Mil) but then increased from Jul. 2023 ($-0.04 Mil) to Jul. 2024 ($0.00 Mil).

Marvel Biosciences Other Operating Expense Historical Data

The historical data trend for Marvel Biosciences's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Other Operating Expense Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Other Operating Expense
-0.04 -0.12 0.04 -0.04 -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.01 - 0.01 -0.09

Marvel Biosciences Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Other Operating Expense
Comparable Companies
TSXV:RKV TSX:APLI XCNQ:NURL XCNQ:ASEP TSXV:XRTX XCNQ:MYND XCNQ:LOBE TSXV:IOT XCNQ:AGN XCNQ:ENBI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.